Qual é o preço para Impel Pharmaceuticals Inc. (IMPL)

O preço para Impel Pharmaceuticals Inc. (IMPL) é $0.1011

Qual é a capitalização de mercado para Impel Pharmaceuticals Inc. (IMPL)

A capitalização de mercado para Impel Pharmaceuticals Inc. (IMPL) é $1.96M

Impel Pharmaceuticals Inc. (IMPL) Rendimento de Dividendos

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.

Ano	Rendimento de Dividendos	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Rendimento de Dividendos

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rendimento de Dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.48%	BE

Empresa

Rendimento de Dividendos

País